TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), today announced that an article was published in the Yale Journal of Biology and Medicine, reporting on the promise of Biovest’s BiovaxID® personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma, an incurable form of blood cancer. The article, titled, “Cancer Immunotherapy Takes a Multi-Faceted Approach to Kick the Immune System into Gear” (Dimberu & Leonhardt), can be accessed in the Media Center at Biovest’s corporate website at: http://www.biovest.com/investor-relations/media-center
